Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
作者信息
Geynisman Daniel M, Ross Eric A, Plimack Elizabeth R
机构信息
Medical Oncology, Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA.
Department of Biostatistics Fox Chase Cancer Center Temple Health, Philadelphia, PA, USA.
出版信息
Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23.
PMID:26116295
Abstract
摘要
相似文献
1
Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
Eur Urol. 2015 Oct;68(4):578-80. doi: 10.1016/j.eururo.2015.06.009. Epub 2015 Jun 23.
2
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
Eur Urol. 2015 Oct;68(4):570-7. doi: 10.1016/j.eururo.2015.04.032. Epub 2015 May 16.
3
Burden of disease matters when it comes to systemic therapy for prostate cancer.
Eur Urol. 2015 Mar;67(3):448-50. doi: 10.1016/j.eururo.2014.02.032. Epub 2014 Feb 22.
4
Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
Eur Urol. 2015 Sep;68(3):e55-6. doi: 10.1016/j.eururo.2015.03.043. Epub 2015 Apr 10.
5
Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
Eur Urol. 2015 Sep;68(3):e57-8. doi: 10.1016/j.eururo.2015.03.042. Epub 2015 Apr 8.
6
STAMPEDE-ing towards androgen biosynthesis inhibition for treatment of high-risk hormone-naïve prostate cancer: changing the LATITUDE.
BJU Int. 2018 Jan;121(1):9-11. doi: 10.1111/bju.14050. Epub 2017 Oct 24.
7
Beyond approval: what is the most appropriate way to use the expanding Armamentarium in metastatic castration-resistant prostate cancer and how do we move forward?
Eur Urol. 2014 Nov;66(5):826-8. doi: 10.1016/j.eururo.2014.03.046. Epub 2014 Apr 13.
8
Timing of androgen deprivation monotherapy and combined treatments in castration-sensitive and castration-resistant prostate cancer: a narrative review.
World J Urol. 2020 Mar;38(3):601-611. doi: 10.1007/s00345-019-02704-y. Epub 2019 Mar 4.
9
Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.
Eur Urol Focus. 2019 Mar;5(2):165-167. doi: 10.1016/j.euf.2018.12.001. Epub 2018 Dec 14.
10
Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study.
Int J Urol. 2016 May;23(5):404-11. doi: 10.1111/iju.13051. Epub 2016 Feb 15.
Zotero 插件